Skip to content
Triangle logo TriangleGet started
← Study library

NCT03155620 · REGISTRY CONDITION SEARCH

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-07-24

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs

→

outcome · NOT POSTED

Objective Response Rate (ORR) to Targeted Therapy in Tumors Lacking Actionable Alterations

→

outcome · NOT POSTED

Genomic Landscape of Advanced Pediatric Solid Tumors, Non-Hodgkin Lymphomas, and Histiocytic Disorders

→

outcome · NOT POSTED

Change in Genomics in Advanced Pediatric Cancers

→

outcome · NOT POSTED

Diagnostic and Profiling Genomics of Tumor Approach

→

outcome · NOT POSTED

Frequency of Germline Cancer Susceptibility Mutations in Children With Relapsed Solid Tumors and Non-Hodgkin Lymphomas

→

outcome · NOT POSTED

Spectrum of Germline Cancer Susceptibility Mutations in Children With Relapsed Solid Tumors and Non-Hodgkin Lymphomas

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must be \>= 12 months and =\< 21 years of age at the time of study enrollment * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients with recurrent or refractory solid tumors, including non-Hodgkin lymphomas, histiocytoses (e.g. langerhans cell histiocytosis \[LCH\], juvenile xanthogranuloma \[JXG\], histiocytic sarcoma), and central nervous system (CNS) tumors are eligible; patients must have had histologic verification of malignancy at original diagnosis or relapse except in patients with intrinsic brain stem tumors, optic pathway gliomas, or patients with pineal tumors and elevations of cerebrospinal fluid (CSF) or serum tumor markers including alpha-fetoprotein or beta-human chorionic gonadotropin (HCG); in cases where patient enrolls prior to histologic confirmation of recurrent disease, patient is ineligible and should be withdrawn from study if histology fails to confirm recurrence; please note: Patients with Hodgkin lymphoma and plexiform neurofibroma are not eligible * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor Testing Requirement: Tumor sample availability requirement for stage 1 of Pediatric MATCH (patients enrolled from start of study in July 2017 through 12/31/21); Patients must have an formalin-fixed paraffin-embedded (FFPE) tumor sample available for MATCH study testing from a biopsy or surgery that was performed at any point after initial tumor recurrence/progression, or be planned to have a procedure to obtain such a sample that is considered to be of potential benefit by the treating clinicians; a tumor sample from a clinically performed diagnostic (pre-treatment) biopsy will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus * Please note: Samples that have been decalcified using standardly utilized acid-based decalcification methods are not generally suitable for MATCH study testing; the nucleic acids will have been degraded in the decalcification process * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Tumor molecular profiling report availability requirement for Stage 2 of Pediatric MATCH (patients enrolled starting 2022): In stage 2 of the study, no tumor samples will be submitted for centralized clinical tumor profiling; instead, a tumor molecular profiling report from a College of American Pathologists (CAP)/ Clinical Laboratory Improvements Amendments (CLIA)-approved testing laboratory must be submitted for review by the Molecular Review Committee (MRC) * This molecular profiling must have been performed on a tumor sample that was obtained at any point after initial tumor recurrence/progression and must be accompanied by a pathology report for the same tumor specimen; a molecular profiling report for a diagnostic (pre-treatment) tumor sample will be acceptable for enrollment onto Pediatric MATCH only for children with high-grade gliomas of the brainstem (diffuse intrinsic pontine gliomas) or thalamus. In the event that molecular profiling reports are available from multiple timepoints, the most recent report should be prioritized for study submission * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age); note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * ELIGIBILITY CRITERIA FOR ENROLLMENT ONTO APEC1621SC: Patients must have radiographically measurable disease; measurable disease based on imaging obtained less than or equal to 56 days prior to enrollment; patients with neuroblastoma who do not have measurable disease but have metaiodobenzylguanidine (MIBG) positive (+) evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard magnetic resonance imaging (MRI) or computed tomography (CT) * Note: The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration except that detected by MIBG scan for neuroblastoma * Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) except as noted for neuroblastoma * Elevated tumor markers in plasma or CSF * Previously radiated lesions that have not demonstrated clear progression post radiation * Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: NOTE: patient does not need to meet all subprotocol criteria at time of enrollment onto the APEC1621SC screening protocol, but will need to meet all criteria prior to enrollment on any assigned treatment subprotocol. Patients must be enrolled onto a subprotocol within 2 weeks (14 days) of treatment assignment * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Karnofsky \>= 50% for patients \> 16 years of age and Lansky \>= 50 for patients =\< 16 years of age); Note: neurologic deficits in patients with CNS tumors must have been stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of treatment with subprotocol specified therapy, the patients must have radiographically measurable disease; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT * Note: The following do not qualify as measurable disease: * Malignant fluid collections (e.g., ascites, pleural effusions) * Bone marrow infiltration except that detected by MIBG scan for neuroblastoma * Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography \[PET\] scans) except as noted for neuroblastoma * Elevated tumor markers in plasma or CSF * Previously radiated lesions that have not demonstrated clear progression post radiation * Leptomeningeal lesions that do not meet the measurement requirements for RECIST 1.1 * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: At the time of enrollment onto a subprotocol, the following general criteria for initiation of therapy will be required: * Patients must have fully recovered from the acute toxic effects of all prior anticancer therapy and must meet the following minimum duration from prior anticancer directed therapy prior to enrollment to the subprotocol; if after the required timeframe, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately * Cytotoxic chemotherapy or other anticancer agents known to be myelosuppressive: for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment \>= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea) * Anticancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil counts \[ANC\]): \>= 7 days after the last dose of agent; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment * Antibodies: \>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =\< 1 * Corticosteroids: If used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid * Hematopoietic growth factors: \>= 14 days after the last dose of a long-acting growth factor (e.g. Neulasta) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator * Interleukins, interferons and cytokines (other than hematopoietic growth factors): \>= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors) * Stem cell infusions (with or without total-body irradiation \[TBI\]): * Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor lymphocyte infusion (DLI) or boost infusion: \>= 84 days after infusion and no evidence of graft versus host disease (GVHD) * Autologous stem cell infusion including boost infusion: \>= 42 days * Cellular therapy: \>= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, natural killer (NK) cells, dendritic cells, etc.) * X-ray therapy (XRT)/External Beam Irradiation including Protons: \>= 14 days after local XRT; \>= 150 days after TBI, craniospinal XRT or if radiation to \>= 50% of the pelvis; \>= 42 days if other substantial bone marrow (BM) radiation; note: radiation may not be delivered to "measurable disease" tumor site(s) being used to follow response to subprotocol treatment * Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): \>= 42 days after systemically administered radiopharmaceutical therapy * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: For patients with solid tumors without known bone marrow involvement: * Peripheral absolute neutrophil count (ANC) \>= 1000/mm\^3 * Platelet count \>= 100,000/mm\^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 ml/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * Age: 1 to \< 2 years; maximum serum creatinine (mg/dL): male 0.6; female 0.6 * Age: 2 to \< 6 years; maximum serum creatinine (mg/dL): male 0.8; female 0.8 * Age: 6 to \< 10 years; maximum serum creatinine (mg/dL): male 1; female 1 * Age: 10 to \< 13 years; maximum serum creatinine (mg/dL): male 1.2; female 1.2 * Age: 13 to \< 16 years; maximum serum creatinine (mg/dL): male 1.5; female 1.4 * Age: \>= 16 years; maximum serum creatinine (mg/dL): male 1.7; female 1.4 * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Bilirubin (sum of conjugated + unconjugated) =\< 1.5 x upper limit of normal (ULN) for age * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Serum glutamate pyruvate transaminase (SGPT) (alanine transferase \[ALT\]) =\< 135 U/L (for the purpose of this study, the ULN for SGPT is 45 U/L) * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Patients must be able to swallow intact capsules/tablets, unless otherwise specified in the subprotocol to which they are assigned * GENERAL INCLUSION CRITERIA FOR SUBPROTOCOLS: Agent specific limitations on prior therapy will be included with specific treatment subprotocols Exclusion Criteria: * GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies, or because there is currently no available information regarding human fetal or teratogenic toxicities; pregnancy tests must be obtained in females who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method * GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Concomitant medications * Corticosteroids: at the time of consent and enrollment to regimen specific subprotocols, patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment to the subprotocol will not be eligible; if used to modify immune adverse events related to prior therapy, \>= 14 days must have elapsed since last dose of corticosteroid * Investigational drugs: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol * Anticancer agents: patients must meet criteria for prior therapy at the time of consent and enrollment to a subprotocol; other investigational agents may not be administered to patients while they are receiving study drug as part of a subprotocol * Anti-GVHD agents post-transplant: patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible * GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have an uncontrolled infection are not eligible * GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Patients who have had a prior solid organ transplant are not eligible * GENERAL EXCLUSION CRITERIA FOR SUBPROTOCOLS: Additional agent specific criteria will be included with specific treatment subprotocols
healthy Volunteers
false
maximum Age
21 Years
minimum Age
12 Months
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate PO or via nasogastric- or gastric-tube BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Drug: Larotrectinib Sulfate
    5. Procedure: Mutation Carrier Screening
    6. Other: Pharmacological Study
    label
    Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    type
    EXPERIMENTAL
  2. description
    Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Procedure: Bone Marrow Aspiration and Biopsy
    4. Procedure: Bone Scan
    5. Procedure: Computed Tomography
    6. Drug: Erdafitinib
    7. Other: Laboratory Biomarker Analysis
    8. Procedure: Magnetic Resonance Imaging
    9. Procedure: Mutation Carrier Screening
    10. Other: Pharmacological Study
    11. Procedure: Radionuclide Imaging
    12. Procedure: X-Ray Imaging
    label
    Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    type
    EXPERIMENTAL
  3. description
    Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Tazemetostat
    label
    Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)
    type
    EXPERIMENTAL
  4. description
    Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Samotolisib
    label
    Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)
    type
    EXPERIMENTAL
  5. description
    Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Selumetinib Sulfate
    label
    Subprotocol E (activating MAPK pathway gene mutation)
    type
    EXPERIMENTAL
  6. description
    Patients with an ALK or ROS1 gene alteration receive ensartinib PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Procedure: Bone Marrow Aspiration and Biopsy
    4. Procedure: Bone Scan
    5. Procedure: Computed Tomography
    6. Drug: Ensartinib
    7. Other: Laboratory Biomarker Analysis
    8. Procedure: Magnetic Resonance Imaging
    9. Procedure: Mutation Carrier Screening
    10. Other: Pharmacological Study
    11. Procedure: Positron Emission Tomography
    12. Procedure: Radionuclide Imaging
    label
    Subprotocol F (ALK or ROS1 gene alteration)
    type
    EXPERIMENTAL
  7. description
    Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Vemurafenib
    label
    Subprotocol G (BRAF V600 gene mutation)
    type
    EXPERIMENTAL
  8. description
    Patients deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Drug: Olaparib
    6. Other: Pharmacological Study
    label
    Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)
    type
    EXPERIMENTAL
  9. description
    Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Drug: Palbociclib
    6. Other: Pharmacological Study
    label
    Subprotocol I (Rb positive, alterations in cell cycle genes)
    type
    EXPERIMENTAL
  10. description
    Patients with MAPK pathway mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Ulixertinib
    label
    Subprotocol J (MAPK pathway mutations)
    type
    EXPERIMENTAL
  11. description
    Patients with IDH1 gene mutations receive ivosidenib PO QD. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Drug: Ivosidenib
    4. Other: Laboratory Biomarker Analysis
    5. Procedure: Mutation Carrier Screening
    6. Other: Pharmacological Study
    label
    Subprotocol K (IDH1 gene mutation)
    type
    EXPERIMENTAL
  12. description
    Patients receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Procedure: Biopsy Procedure
    2. Procedure: Biospecimen Collection
    3. Other: Laboratory Biomarker Analysis
    4. Procedure: Mutation Carrier Screening
    5. Other: Pharmacological Study
    6. Drug: Tipifarnib
    label
    Subprotocol M (HRAS gene alterations)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    2. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    3. Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)
    4. Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)
    5. Subprotocol E (activating MAPK pathway gene mutation)
    6. Subprotocol F (ALK or ROS1 gene alteration)
    7. Subprotocol G (BRAF V600 gene mutation)
    8. Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)
    9. Subprotocol I (Rb positive, alterations in cell cycle genes)
    10. Subprotocol J (MAPK pathway mutations)
    11. Subprotocol K (IDH1 gene mutation)
    12. Subprotocol M (HRAS gene alterations)
    description
    Undergo biopsy
    name
    Biopsy Procedure
    other Names
    1. Biopsy
    2. BIOPSY_TYPE
    3. Bx
    type
    PROCEDURE
  2. arm Group Labels
    1. Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    2. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    3. Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)
    4. Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)
    5. Subprotocol E (activating MAPK pathway gene mutation)
    6. Subprotocol F (ALK or ROS1 gene alteration)
    7. Subprotocol G (BRAF V600 gene mutation)
    8. Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)
    9. Subprotocol I (Rb positive, alterations in cell cycle genes)
    10. Subprotocol J (MAPK pathway mutations)
    11. Subprotocol K (IDH1 gene mutation)
    12. Subprotocol M (HRAS gene alterations)
    description
    Undergo blood sample collection
    name
    Biospecimen Collection
    other Names
    1. Biological Sample Collection
    2. Biospecimen Collected
    3. Sample Collection
    4. Specimen Collection
    type
    PROCEDURE
  3. arm Group Labels
    1. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    2. Subprotocol F (ALK or ROS1 gene alteration)
    description
    Undergo a bone marrow and/or biopsy
    name
    Bone Marrow Aspiration and Biopsy
    type
    PROCEDURE
  4. arm Group Labels
    1. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    2. Subprotocol F (ALK or ROS1 gene alteration)
    description
    Undergo a bone scan
    name
    Bone Scan
    other Names
    1. Bone Scintigraphy
    type
    PROCEDURE
  5. arm Group Labels
    1. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    2. Subprotocol F (ALK or ROS1 gene alteration)
    3. Subprotocol N (activating RET mutations)
    description
    Undergo CT, PET/Ct, and/or CT/MRI
    name
    Computed Tomography
    other Names
    1. CAT
    2. CAT Scan
    3. Computed Axial Tomography
    4. Computerized Axial Tomography
    5. Computerized axial tomography (procedure)
    6. Computerized Tomography
    7. Computerized Tomography (CT) scan
    8. CT
    9. CT Scan
    10. Diagnostic CAT Scan
    11. Diagnostic CAT Scan Service Type
    12. tomography
    type
    PROCEDURE
  6. arm Group Labels
    1. Subprotocol F (ALK or ROS1 gene alteration)
    description
    Given PO
    name
    Ensartinib
    other Names
    1. X 396
    2. X-396
    3. X396
    type
    DRUG
  7. arm Group Labels
    1. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    description
    Given PO
    name
    Erdafitinib
    other Names
    1. Balversa
    2. JNJ 42756493
    3. JNJ-42756493
    4. JNJ42756493
    type
    DRUG
  8. arm Group Labels
    1. Subprotocol K (IDH1 gene mutation)
    description
    Given PO
    name
    Ivosidenib
    other Names
    1. AG 120
    2. AG-120
    3. AG120
    4. Tibsovo
    type
    DRUG
  9. arm Group Labels
    1. Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    2. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    3. Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)
    4. Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)
    5. Subprotocol E (activating MAPK pathway gene mutation)
    6. Subprotocol F (ALK or ROS1 gene alteration)
    7. Subprotocol G (BRAF V600 gene mutation)
    8. Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)
    9. Subprotocol I (Rb positive, alterations in cell cycle genes)
    10. Subprotocol J (MAPK pathway mutations)
    11. Subprotocol K (IDH1 gene mutation)
    12. Subprotocol M (HRAS gene alterations)
    description
    Undergo molecular analysis
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  10. arm Group Labels
    1. Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    description
    Given PO or via nasogastric- or gastric-tube
    name
    Larotrectinib Sulfate
    other Names
    1. ARRY 470 Sulfate
    2. LOXO 101 Sulfate
    3. LOXO-101 Sulfate
    4. Vitrakvi
    type
    DRUG
  11. arm Group Labels
    1. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    2. Subprotocol F (ALK or ROS1 gene alteration)
    3. Subprotocol N (activating RET mutations)
    description
    Undergo MRI, PET/MRI, and/or CT/MRI
    name
    Magnetic Resonance Imaging
    other Names
    1. Magnetic Resonance
    2. Magnetic Resonance Imaging (MRI)
    3. Magnetic resonance imaging (procedure)
    4. Magnetic Resonance Imaging Scan
    5. Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    6. MR
    7. MR Imaging
    8. MRI
    9. MRI Scan
    10. MRIs
    11. NMR Imaging
    12. NMRI
    type
    PROCEDURE
  12. arm Group Labels
    1. Subprotocol A (NTRK1, NTRK2, or NTRK3 gene fusion)
    2. Subprotocol B (FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation)
    3. Subprotocol C (EZH2, SMARCB1, or SMARCA4 gene mutation)
    4. Subprotocol D (TSC1, TSC2, or PI3K/mTOR gene mutation)
    5. Subprotocol E (activating MAPK pathway gene mutation)
    6. Subprotocol F (ALK or ROS1 gene alteration)
    7. Subprotocol G (BRAF V600 gene mutation)
    8. Subprotocol H (ATM, BRCA1, BRCA2, RAD51C, RAD51D mutations)
    9. Subprotocol I (Rb positive, alterations in cell cycle genes)
    10. Subprotocol J (MAPK pathway mutations)
    11. Subprotocol K (IDH1 gene mutation)
    12. Subprotocol M (HRAS gene alterations)
    description
    Undergo tumor tissue mutation screening
    name
    Mutation Carrier Screening
    type
    PROCEDURE
Study design
allocation
NON_RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
SCREENING
Enrollment
count
1377
type
ACTUAL
Registered outcome plans (not posted results)
other Outcomes
  1. description
    A descriptive analysis will be performed and will be summarized with simple summary statistics. This analysis will be descriptive in nature.
    measure
    Genomic Landscape of Advanced Pediatric Solid Tumors, Non-Hodgkin Lymphomas, and Histiocytic Disorders
    time Frame
    Up to 4 years
  2. description
    A descriptive analysis will be performed and will be summarized with simple summary statistics. This analysis will be descriptive in nature.
    measure
    Change in Genomics in Advanced Pediatric Cancers
    time Frame
    Baseline up to 4 years
  3. description
    Will be evaluated through circulating tumor deoxyribonucleic acid (DNA). A descriptive analysis will be performed and will be summarized with simple summary statistics. This analysis will be descriptive in nature.
    measure
    Diagnostic and Profiling Genomics of Tumor Approach
    time Frame
    Up to 4 years
  4. description
    A descriptive analysis will be performed and will be summarized with simple summary statistics. This analysis will be descriptive in nature. Will assess the feasibility of return of the results in the National Clinical Trial Network (NCTN) group setting.
    measure
    Frequency of Germline Cancer Susceptibility Mutations in Children With Relapsed Solid Tumors and Non-Hodgkin Lymphomas
    time Frame
    Up to 4 years
  5. description
    A descriptive analysis will be performed and will be summarized with simple summary statistics. This analysis will be descriptive in nature. Will assess the feasibility of return of the results in the NCTN group setting.
    measure
    Spectrum of Germline Cancer Susceptibility Mutations in Children With Relapsed Solid Tumors and Non-Hodgkin Lymphomas
    time Frame
    Up to 4 years
primary Outcomes
  1. description
    Match rate will be calculated as the percent of eligible patients who have an actionable mutation of interest and are matched to at least one of the subprotocols, and confidence intervals will be constructed using the Wilson score interval method. Patients enrolled on or after Amendment 4 will not be included in this analysis as screening of unselected patients will no longer be conducted.
    measure
    Proportion of Pediatric Patients Whose Advanced Tumors Have Pathway Alterations That Can be Targeted by Select Anti-cancer Drugs
    time Frame
    Up to 2 years from study entry
secondary Outcomes
  1. description
    Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method.
    measure
    Objective Response Rate (ORR) to Targeted Therapy in Tumors Lacking Actionable Alterations
    time Frame
    Up to 2 years from study entry
Full study description
brief Summary
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
detailed Description
PRIMARY OBJECTIVES: I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs. (Completed as of Amendment #4. Patients enrolled on or after Amendment 4 will not be included in this analysis as screening of unselected patients will no longer be conducted.) SECONDARY OBJECTIVE: I. To obtain preliminary information on the response rate to targeted therapy in patients whose tumors lack actionable alterations as defined for the molecular analysis for therapy choice (MATCH) study, for selected agents for which efficacy is observed in the primary matched cohort. EXPLORATORY OBJECTIVES: I. To increase knowledge of the genomic landscape of advanced pediatric solid tumors, non-Hodgkin lymphomas, and histiocytic disorders. II. To describe the genomic changes that occur in advanced pediatric cancers between the time of initial diagnosis and relapse, in cases for which paired tumor specimens are available. III. To explore approaches to diagnosing and profiling genomics of advanced pediatric cancers through evaluation of circulating tumor deoxyribonucleic acid (DNA). IV. To determine the frequency and spectrum of germline cancer susceptibility mutations in children with relapsed solid tumors and non-Hodgkin lymphomas and assess the feasibility of return of those results in the National Clinical Trial Network (NCTN) group setting. OUTLINE: STEP 1 (SCREENING): Patients undergo biopsy along with tumor mutational screening of the biopsy material for specific, pre-defined mutations, amplifications, or translocations of interest via tumor sequencing and immunohistochemistry. Patients also undergo collection of blood samples for research purposes. STEP 2 (TREATMENT): Patients with a mutation targeted by one or more of the investigational drugs used in this study or those without mutations are assigned to 1 of 13 treatment subprotocols. APEC1621A: Patients with a NTRK1, NTRK2, or NTRK3 gene fusion receive larotrectinib sulfate orally (PO) or via nasogastric- or gastric-tube twice daily (BID) on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621B: Patients with a FGFR1, FGFR2, FGFR3, or FGFR4 gene mutation receive erdafitinib PO once daily (QD) on days 1-28 of each cycle. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, computed tomography (CT scan), magnetic resonance imaging (MRI), radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study. APEC1621C: Patients with an EZH2, SMARCB1, or SMARCA4 gene mutation receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621D: Patients with a TSC1, TSC2, or PI3K/mTOR gene mutations receive PI3K/mTOR inhibitor LY3023414 PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621E: Patients with an activating MAPK pathway gene mutation receive selumetinib sulfate PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621F: Patients with an ALK or ROS1 gene alteration receive ensartinib (ALK Inhibitor X-396) PO BID on days 1-28. Cycles repeat every 28 days for 2 years (up to 26 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo an x-ray, CT scan, MRI, PET scan, radionuclide imaging, and/or bone scan, as well as a bone marrow aspiration and/or biopsy during screening and on study. Patients also undergo blood sample collection on study. APEC1621G: Patients with a BRAF V600 gene mutation receive vemurafenib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621H: Patients with deleterious ATM, BRCA1, BRCA2, RAD51C, or RAD51D gene mutations receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity. APEC1621I: Patients with Rb positive advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations in cell cycle genes receive palbociclib PO QD on days 1-21. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. APEC1621J: Patients with MAPK Pathway Mutations receive ulixertinib PO BID. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. APEC1621K: Patients with IDH1 gene mutations receive ivosidenib PO QD. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. APEC1621M: Patients with HRAS gene alterations receive tipifarnib PO or via nasogastric or gastric tube BID on days 1-7 and 15-21. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. APEC1621N: Patients with activating RET gene alterations receive selpercatinib PO BID on days 1-28. Treatment repeats every 28 days for up to 26 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Patients may also undergo PET, CT, MRI, PET/CT, PET/MRI, and/or CT/MRI, scintigraphy, and x-ray imaging throughout the trial. After completion of study treatment, patients are followed up periodically.
Source references
references
  1. citation
    Scollon S, Plon SE, Joffe S, Biegel JA, Kulkarni S, Miles G, Patton DR, Coffey B, Winter CL, Tsongalis GJ, Routbort MJ, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Weigel B, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW; NCI-COG Pediatric MATCH Germline Reporting Committee. Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2025 Oct;9:e2500742. doi: 10.1200/PO-25-00742. Epub 2025 Oct 30.
    pmid
    41166674
    type
    DERIVED
  2. citation
    Parsons DW, Janeway KA, Patton DR, Winter CL, Coffey B, Williams PM, Roy-Chowdhuri S, Tsongalis GJ, Routbort M, Ramirez NC, Saguilig L, Piao J, Alonzo TA, Berg SL, Fox E, Hawkins DS, Abrams JS, Mooney M, Takebe N, Tricoli JV, Seibel NL; NCI-COG Pediatric MATCH Team. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 Jul 10;40(20):2224-2234. doi: 10.1200/JCO.21.02838. Epub 2022 Mar 30.
    pmid
    35353553
    type
    DERIVED
  3. citation
    Jain J, Sutton KS, Hong AL. Progress Update in Pediatric Renal Tumors. Curr Oncol Rep. 2021 Feb 16;23(3):33. doi: 10.1007/s11912-021-01016-y.
    pmid
    33591402
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5a68ae2f1a7d1c7e8b5e
      requested nct id
      NCT03155620
      primary nct id
      NCT03155620
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      5133d5efc2041fb2554b035b378f2db0c15cad34dada88cd170d20b9c4e7432a
      payload sha256
      899ce5770f3e29249a4d396151e9667774aef6737c61cdf43007d4bbd1e055ba
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5a68ae2f1a7d1c7e8b5e
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03155620
      occurrences
      1. context exact
        NCT03155620
        end
        11
        exact text
        NCT03155620
        start
        0
      offset unit
      unicode_code_points
      query cond
      Primary Central Nervous System Lymphoma
      query disease state id
      ds-primary-central-nervous-system-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-primary-central-nervous-system-lymphoma-000.json
      source file sha256
      5133d5efc2041fb2554b035b378f2db0c15cad34dada88cd170d20b9c4e7432a
      source json pointer
      /studies/18/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5a159dbc737c166033f5782240c056709cd1db82b3b2853bb59ecbcc51def18b
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-a3afeea840fc0f7c59be
      requested nct id
      NCT03155620
      primary nct id
      NCT03155620
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      payload sha256
      3cd9d8b7a6cb1c550aece3cb1a860cd0b63123b3b353b8b65ca91d5a1d1864f8
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-a3afeea840fc0f7c59be
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03155620
      occurrences
      1. context exact
        NCT03155620
        end
        11
        exact text
        NCT03155620
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Kidney Tumors
      query disease state id
      ds-childhood-kidney-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-kidney-tumors-000.json
      source file sha256
      0f0b1d47d700cf556d6212d53b7849c30874e411dbc1a4cfc2cbeef7e5d70ca8
      source json pointer
      /studies/5/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5a159dbc737c166033f5782240c056709cd1db82b3b2853bb59ecbcc51def18b
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f6ec76f41e98b25b1fa4
      requested nct id
      NCT03155620
      primary nct id
      NCT03155620
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      86f3ecb5cbeba3a0a50bac9fe3795ef3e834512a393e2263638362dc3db24a08
      payload sha256
      ff3e99776032a53d37e54f3663f264575aab24a57f163987072e19786c0a1e3b
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f6ec76f41e98b25b1fa4
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03155620
      occurrences
      1. context exact
        NCT03155620
        end
        11
        exact text
        NCT03155620
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor
      query disease state id
      ds-central-nervous-system-atypical-teratoid-rhabdoid-tumor-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-central-nervous-system-atypical-teratoid-rhabdoid--000.json
      source file sha256
      86f3ecb5cbeba3a0a50bac9fe3795ef3e834512a393e2263638362dc3db24a08
      source json pointer
      /studies/2/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      5a159dbc737c166033f5782240c056709cd1db82b3b2853bb59ecbcc51def18b

    Preserved source evidence · Not medical advice